NeuroPace Return on Equity

NeuroPace (NPCE) currently reports a ROE of -160.85%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore NeuroPace's ROE history and peer comparisons.

NeuroPace's ROE of -160.85% is lower than the Healthcare sector average of 20.77%. That is roughly 874.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NeuroPace's current -160.85% should be judged against Healthcare norms (sector average: 20.77%) and against NPCE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -160.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for NeuroPace, and consider following NPCE for alerts when major investors trade the stock.

NeuroPace is classified in the Healthcare sector. On ROE, it currently shows -160.85% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NPCE with unrelated industries.